Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 10/2005

01-10-2005 | Letter to the Editor

Successful treatment of a patient with myelodysplastic syndrome (RAEB) with Darbepoetin-alfa in combination with Pegfilgrastim

Authors: Andreas Jakob, Friedrich W. Hirsch, Monika Engelhardt

Published in: Annals of Hematology | Issue 10/2005

Login to get access

Excerpt

Dear Editor, …
Literature
1.
Casadevall N, Durieux P, Dubois S et al (2004) Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood 104:321–327CrossRefPubMed
2.
Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G et al (2003) A validated decision model for treating the anemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 120:1037–1046CrossRefPubMed
3.
4.
Kasper C, Zahner J, Sayer HG (2002) Recombinant human erythropoietin in combined treatment with granulocyte- or granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. J Cancer Res Clin Oncol 128:497–502
5.
Musto P, Sanpaolo G, D’Arena G et al (2001) Adding growth factors or IL-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone. Haematologica 86:44–51PubMed
6.
Tehranchi R, Fadeel B, Forsblom AM et al (2003) Granulocyte colony-stimulating factor inhibits spontaneous cytochrome c release and mitochondria-dependent apoptosis of myelodysplastic syndrome hematopoietic progenitors. Blood 101:1080–1086CrossRefPubMed
7.
Rigolin GM, Porta MD, Ciccone M et al (2004) In patients with myelodysplastic syndromes response to rhEPO and G-CSF treatment is related to an increase of cytogenetically normal CD34 cells. Br J Haematol 126:501–507CrossRefPubMed
8.
Cheson BD, Bennett JM, Kantarjian H et al (2000) Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 96:3671–3674PubMed
9.
Musto P, Lanza F, Balleari E et al (2004) Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes. Br J Haematol 128:204–209CrossRef
10.
Spiriti MAA, Latagliata R, Niscola P et al (2005) Impact of a new dosing regimen of epoetin alfa on quality of life an anemia in patients with low-risk myelodysplastic syndrome. Ann Hematol 84:167–176CrossRefPubMed
Metadata
Title
Successful treatment of a patient with myelodysplastic syndrome (RAEB) with Darbepoetin-alfa in combination with Pegfilgrastim
Authors
Andreas Jakob
Friedrich W. Hirsch
Monika Engelhardt
Publication date
01-10-2005
Publisher
Springer-Verlag
Published in
Annals of Hematology / Issue 10/2005
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-005-1060-2

Other articles of this Issue 10/2005

Annals of Hematology 10/2005 Go to the issue

Review Article

Recent acquisitions in the management of iron overload

Original Article

Frequency and clinical expression of HFE gene mutations in a Spanish population of subjects with abnormal iron metabolism

Letter to the Editor

Typhlitis associated with Candida albicans and Pseudomonas aeruginosa infection in a patient with herbal drug-induced neutropenia

Original Article

Plasma antigen levels of thrombin-activatable fibrinolysis inhibitor did not differ in patients with or without disseminated intravascular coagulation

Short Communication

Mutations of the HFE gene among Turkish hereditary hemochromatosis patients

Original Article

Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits